In the first big merger of 2019, Bristol-Myers Squibb (NYSE:BMY) agreed to acquire Celgene (NASDAQ: CELG) for about $74B, combining two of the world's largest

The first big merger of 2019, Bristol-Myers Squibb

FANDOM FARE

Fandomfare Gaming Pop up Health care News

In the first big merger of 2019, Bristol-Myers Squibb (NYSE:BMY) agreed to acquire Celgene (NASDAQ: CELG) for about $74B, combining two of the world’s largest cancer drug businesses. Both Bristol and Celgene entered the new year facing challenges of cash flow and growth, and some Wall Street analysts questioned whether the combination – which would create $2.5B in cost savings and significantly raise earnings – would solve them.

the pharma monster Bristol-Myers Squibb has gobbled up the biotech goliath Celgene in a $74 billion arrangement.

Celgene investors will get one BMS share and $50 money for each Celgene share they possess, esteeming the New Jersey-based Celgene at about $102.43 an offer, as per the organizations. That is about 54% more than Celgene’s end cost on Wednesday.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.